by Elena Iemma | Jul 29, 2025 | Blog
Optimize Your Immunogenicity Strategy with Trusted Expert Advice Immunogenicity is a critical factor in biologic drug development, with the potential to determine a therapy’s success or failure. Undesirable immune responses, including the formation of anti-drug...
by Elena Iemma | Jul 17, 2025 | Blog
Tregs, Epitopes, and the Future of Immune Tolerance Making Sense of Natural Constraint Contrary to popular (immunologist) belief, there’s nothing ‘non-specific’ about Tregs! Otherwise why would they carry TCR (T cell receptors) that bind to their...
by Elena Iemma | May 28, 2025 | Blog, Uncategorized
The new CSO starts on June 1st! Drumroll please…. We are pleased to welcome Dr. Vibha Jawa as the new Chief Scientific Officer at EpiVax! Please see this link for more information about this latest update to EpiVax 2.0. (I will be around to help transition)....
by Elena Iemma | May 19, 2025 | Blog
FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...
by Elena Iemma | Apr 30, 2025 | Blog
Is “Artificial” Intelligence an Option for your ADA? In Case You Missed It: Better ADA Prediction! Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved...
by Elena Iemma | Mar 1, 2025 | Blog
The EpiVax team is dedicated to advancing the science of immunogenicity assessment and streamlining the preclinical drug development process for our partners worldwide. This month, we’re excited to share several updates with you, including new and updated in silico...
